Sepracor and Bial to develop epilepsy drug BIA 2-093 for the USA in $175M deal
Massachusetts, USA-based pharmaceutical firm Sepracor and Portugal's Bial have entered into an exclusive licensing agreement covering the latter's candidate anti-epileptic BIA 2-093 (eslicarbazepine acetate). The deal will see the companies collaborate on development and commercialization of the compound for the US and Canadian epilepsy markets.
Previous Ph III studies suggest efficacy
BIA 2-093 is designed to provide sufferers of partial epilepsy with improved seizure control and, at present, is being examined in adult patients as an adjunctive therapy. A previous Phase III study, in which more than 1,000 subjects in 22 countries were randomized to receive 18 weeks of treatment, indicated that the drug was safe and effective.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze